IBANDRONIC ACID

BRAND NAME	BONDRONAT
DRUG CLASS	Bisphosphonate
AVAILABILITY	Vial contains 6 mg/6 mL of ibandronic acid as ibandronate sodium monohydrate. Also contains sodium chloride, glacial acetic acid and sodium acetate.[1] The solution is clear and colourless.[1]
pH	No information
PREPARATION	Dilute before use[1]
STABILITY	Vial: store below 30 °C.[1] Infusion solution: stable for 24 hours at 2 to 8 °C.[1]
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Dilute the dose with 500 mL of a compatible fluid and infuse over 1 to 2 hours.[1] For prevention of skeletal events in patients with breast cancer and with normal renal function dilute the dose with 100 mL of sodium chloride 0.9% and infuse over at least 15 minutes.[2]
COMPATIBILITY	
Fluids	Glucose 5%[1], sodium chloride 0.9%[1]
Y-site	No information
INCOMPATIBILITY	
Fluids	Solutions that contain calcium e.g. Hartmann's[1]
Drugs	No information
SPECIAL NOTES	Extravasation can cause tissue damage[1]. Monitor the injection site. Flu-like symptoms may occur in the days following the infusion.[2] Paracetamol may ease symptoms. Anaphylactic reactions are rare but are a medical emergency.[1] Stop the infusion and commence treatment immediately.

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 18/10/2019.
2. Bondronat 6mg concentrate for solution for infusion. Summary of product characteristics. Basildon, Essex: Atnahs Pharma UK. Approved 25/06/1996. Updated 25/05/2006. Revised 20/05/2019. Available from www.medicines.org.uk. Accessed 18/10/2019.